Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TAK 044

Known as: TAK-044 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Objective and background:  Pulmonary fibrosis in sarcoidosis is a significant cause of morbidity and mortality. Various factors… Expand
Highly Cited
2005
Highly Cited
2005
Stroke causes brain injury in millions of people world wide each year. Despite the enormity of problem, currently there is no… Expand
Highly Cited
2000
Highly Cited
2000
OBJECT Delayed cerebral ischemia remains an important cause of death and disability in patients who have suffered subarachnoid… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Highly Cited
2000
Highly Cited
2000
Object. Delayed cerebral ischemia remains an important cause of death and disability in patients who have suffered subarachnoid… Expand
Highly Cited
1998
Highly Cited
1998
Hepatic levels of a powerful vasoconstrictor endothelin-1 (ET-1) and its receptors increase in human and carbon tetrachloride… Expand
Highly Cited
1996
Highly Cited
1996
BACKGROUND Although local inhibition of the generation or actions of endothelin-1 has been shown to cause forearm vasodilatation… Expand
Highly Cited
1996
Highly Cited
1996
1 We examined the effects of systemic infusion, in healthy human volunteers, of the endothelin antagonist TAK‐044 on the plasma… Expand
Highly Cited
1995
Highly Cited
1995
1 The aims of the present study were to characterize the pharmacological profile of a new endothelin (ET) receptor antagonist… Expand
Highly Cited
1994
Highly Cited
1994
Protective effects of a new endothelin (ET) receptor antagonist, TAK-044, were studied in a model of acute renal failure (ARF) in… Expand
Highly Cited
1994
Highly Cited
1994
The present study describes the pharmacological profile of an endothelin (ET) receptor antagonist, TAK-044, in anesthetized rats… Expand